Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. / Hansen, Jakob Werner; Westman, Maj Karoline; Sjö, Lene Dissing; Saft, Leonie; Sommer Kristensen, Lasse; Ørskov, Andreas Due; Treppendahl, Marianne; Andersen, Mette Klarskov; Grønbaek, Kirsten.

In: American Journal of Hematology, Vol. 91, No. 12, 12.2016, p. 1234-1238.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hansen, JW, Westman, MK, Sjö, LD, Saft, L, Sommer Kristensen, L, Ørskov, AD, Treppendahl, M, Andersen, MK & Grønbaek, K 2016, 'Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes', American Journal of Hematology, vol. 91, no. 12, pp. 1234-1238. https://doi.org/10.1002/ajh.24554

APA

Hansen, J. W., Westman, M. K., Sjö, L. D., Saft, L., Sommer Kristensen, L., Ørskov, A. D., Treppendahl, M., Andersen, M. K., & Grønbaek, K. (2016). Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. American Journal of Hematology, 91(12), 1234-1238. https://doi.org/10.1002/ajh.24554

Vancouver

Hansen JW, Westman MK, Sjö LD, Saft L, Sommer Kristensen L, Ørskov AD et al. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. American Journal of Hematology. 2016 Dec;91(12):1234-1238. https://doi.org/10.1002/ajh.24554

Author

Hansen, Jakob Werner ; Westman, Maj Karoline ; Sjö, Lene Dissing ; Saft, Leonie ; Sommer Kristensen, Lasse ; Ørskov, Andreas Due ; Treppendahl, Marianne ; Andersen, Mette Klarskov ; Grønbaek, Kirsten. / Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. In: American Journal of Hematology. 2016 ; Vol. 91, No. 12. pp. 1234-1238.

Bibtex

@article{658637a54e5d43c0be562ee104c16316,
title = "Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes",
abstract = "Cytopenia is common in the elderly population and etiology may be difficult to assess. Here, we investigated the occurrence of mutations in patients with idiopathic cytopenia of undetermined significance and the usefulness in improving diagnostics. We included 60 patients with persistent cytopenia > 6 months without definite diagnosis of hematological neoplasm after routine assessment. Bone marrow material underwent a blinded morphology review and DNA was sequenced with a targeted 20 gene panel representing the most commonly mutated genes in myelodysplastic syndrome. Thirty seven (62%) patients carried at least one mutation at inclusion, and of these 95% carried a mutation in TET2, ASXL1, SRSF2, or DNMT3A. The most commonly mutated gene was TET2 observed in 43% of all patients. During one to eight years follow-up seven patients progressed to a myeloid neoplasm and six of these had a detectable mutation at study entry. Median time to progression was 53 months (range 10-78), and at time of progression each patient had at least two mutations detected. Mutations in TP53 and NRAS were not present in patients at inclusion, but identified as secondary hits triggering progression. The morphology review was concordant in 68% of all cases, and 93% of the cases reclassified into the group {"}highly suspicious for MDS{"} had a mutation. All patients who had a concordant review {"}highly suspicious for MDS{"} had at least two mutations detected. Overall, we show that morphology examination is challenging in this heterogeneous group and targeted sequencing helps identify patients at risk of progression. Am. J. Hematol. 91:1234-1238, 2016. {\textcopyright} 2016 Wiley Periodicals, Inc.",
author = "Hansen, {Jakob Werner} and Westman, {Maj Karoline} and Sj{\"o}, {Lene Dissing} and Leonie Saft and {Sommer Kristensen}, Lasse and {\O}rskov, {Andreas Due} and Marianne Treppendahl and Andersen, {Mette Klarskov} and Kirsten Gr{\o}nbaek",
note = "{\textcopyright} 2016 Wiley Periodicals, Inc.",
year = "2016",
month = dec,
doi = "10.1002/ajh.24554",
language = "English",
volume = "91",
pages = "1234--1238",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "JohnWiley & Sons, Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes

AU - Hansen, Jakob Werner

AU - Westman, Maj Karoline

AU - Sjö, Lene Dissing

AU - Saft, Leonie

AU - Sommer Kristensen, Lasse

AU - Ørskov, Andreas Due

AU - Treppendahl, Marianne

AU - Andersen, Mette Klarskov

AU - Grønbaek, Kirsten

N1 - © 2016 Wiley Periodicals, Inc.

PY - 2016/12

Y1 - 2016/12

N2 - Cytopenia is common in the elderly population and etiology may be difficult to assess. Here, we investigated the occurrence of mutations in patients with idiopathic cytopenia of undetermined significance and the usefulness in improving diagnostics. We included 60 patients with persistent cytopenia > 6 months without definite diagnosis of hematological neoplasm after routine assessment. Bone marrow material underwent a blinded morphology review and DNA was sequenced with a targeted 20 gene panel representing the most commonly mutated genes in myelodysplastic syndrome. Thirty seven (62%) patients carried at least one mutation at inclusion, and of these 95% carried a mutation in TET2, ASXL1, SRSF2, or DNMT3A. The most commonly mutated gene was TET2 observed in 43% of all patients. During one to eight years follow-up seven patients progressed to a myeloid neoplasm and six of these had a detectable mutation at study entry. Median time to progression was 53 months (range 10-78), and at time of progression each patient had at least two mutations detected. Mutations in TP53 and NRAS were not present in patients at inclusion, but identified as secondary hits triggering progression. The morphology review was concordant in 68% of all cases, and 93% of the cases reclassified into the group "highly suspicious for MDS" had a mutation. All patients who had a concordant review "highly suspicious for MDS" had at least two mutations detected. Overall, we show that morphology examination is challenging in this heterogeneous group and targeted sequencing helps identify patients at risk of progression. Am. J. Hematol. 91:1234-1238, 2016. © 2016 Wiley Periodicals, Inc.

AB - Cytopenia is common in the elderly population and etiology may be difficult to assess. Here, we investigated the occurrence of mutations in patients with idiopathic cytopenia of undetermined significance and the usefulness in improving diagnostics. We included 60 patients with persistent cytopenia > 6 months without definite diagnosis of hematological neoplasm after routine assessment. Bone marrow material underwent a blinded morphology review and DNA was sequenced with a targeted 20 gene panel representing the most commonly mutated genes in myelodysplastic syndrome. Thirty seven (62%) patients carried at least one mutation at inclusion, and of these 95% carried a mutation in TET2, ASXL1, SRSF2, or DNMT3A. The most commonly mutated gene was TET2 observed in 43% of all patients. During one to eight years follow-up seven patients progressed to a myeloid neoplasm and six of these had a detectable mutation at study entry. Median time to progression was 53 months (range 10-78), and at time of progression each patient had at least two mutations detected. Mutations in TP53 and NRAS were not present in patients at inclusion, but identified as secondary hits triggering progression. The morphology review was concordant in 68% of all cases, and 93% of the cases reclassified into the group "highly suspicious for MDS" had a mutation. All patients who had a concordant review "highly suspicious for MDS" had at least two mutations detected. Overall, we show that morphology examination is challenging in this heterogeneous group and targeted sequencing helps identify patients at risk of progression. Am. J. Hematol. 91:1234-1238, 2016. © 2016 Wiley Periodicals, Inc.

U2 - 10.1002/ajh.24554

DO - 10.1002/ajh.24554

M3 - Journal article

C2 - 27717004

VL - 91

SP - 1234

EP - 1238

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -

ID: 173808547